Navigation Links
HORIZONS-AMI Trial Provides Superior Outcomes Data at Three Years with TAXUS® Drug-Eluting Stent in Heart Attack Patients
Date:9/25/2010

US Express vs. 15.1 percent for bare-metal Express (p<0.001), a relative reduction of 40 percent.  The secondary efficacy endpoint of ischemia-driven target vessel revascularization (TVR) was 12.4 percent for TAXUS Express vs. 17.6 percent for bare-metal Express (p<0.001), a relative reduction of 32 percent.

The primary safety endpoint of major adverse cardiac events (MACE) at three years was comparable for TAXUS Express and bare-metal Express patients (13.6 percent vs. 12.9 percent, respectively, p=0.66), which is consistent with findings at one and two years.  Individual rates of death, repeat heart attack, stroke and stent thrombosis between the two groups through three years of follow-up were also comparable.  

"Results from the HORIZONS-AMI trial continue to show the impressive benefits of paclitaxel-eluting stent technology in this important high-risk AMI patient population," said Keith D. Dawkins, M.D., Senior Vice President and Chief Medical Officer for Boston Scientific's Cardiology, Rhythm and Vascular Group.  "Boston Scientific continues to support large clinical trials that provide the medical community data that can be used in combination with broader clinical judgment to develop optimal treatment strategies for challenging patient subsets."

The TAXUS Express Stent and the Express Stent are not specifically indicated by the U.S. Food and Drug Administration for use in patients with AMI.  

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. Titled ... model developed at UH to enhance care for adult ... need for high health care utilization.  ...
(Date:7/10/2014)... DIEGO , July 10, 2014  RESMED INC. (NYSE: ... its fourth quarter and fiscal year ended June 30, 2014 ... Stock Exchange market close. A press release with ResMed,s results ... the company will host a webcast to discuss operating results ... to begin at 1:30 p.m. US Pacific Time and the ...
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... 30, 2011 David N. Jonas, CEO, PharMEDium ... investments for innovations with an unprecedented focus on ... with a steady stream of technologically-driven service advancements.  Working ... safety and quality , PharMEDium ...
... 30, 2011 Reportlinker.com announces that a new ... catalogue: Pharmaceutical Distributors - ... This register contains information ... Europe. The register includes the following information ...
Cached Medicine Technology:PharMEDium's Technology Helps Hospital Pharmacists Ensure Safety 2
(Date:7/11/2014)... July 11, 2014 Global enterprises today ... to outsource day-to-day management activities. Managed services offer these ... expenses. The economic slowdown resulted into rising operational costs ... expenses is considered to be the global market driver ... , The global managed services market is estimated to ...
(Date:7/11/2014)... Presently, disposable medical suppliers call for ... supplies segment. During the past two decades, the world ... an average 12.5% per year), primarily owing to the ... US is the largest market for disposable medical supplies ... The second position is held by Europe with a ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... has found that organic foods and crops have ... including more antioxidants and fewer, less frequent pesticide ... 343 peer-reviewed publications comparing the nutritional quality and ... fruits, vegetables, and grains. The study team applied ... and non-organic foods. , "Science marches on," ...
(Date:7/11/2014)... (HealthDay News) -- Delaying surgery to repair damage to the ... middle of the knee -- could increase a young athlete,s ... medical records of 130 patients, aged 8 to 16, who ... less than six weeks after their injury, 37 had surgery ... more than three months after their injury. The youngsters ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
... Severe early childhood caries can destroy most of a ... populations, including American Indians and Alaskan natives. Although the ... early childhood caries has been known for almost a ... are responsible for the disease has remained elusive. ...
... The American College of Physicians (ACP) today told the ... including enacting a permanent end to scheduled Medicare sustainable ... for Congress to act was demonstrated by today,s release ... across-the-board cut in Medicare payments to doctors on January ...
... (HealthDay News) -- Allergy shots are time-tested treatments ... relief to allergy sufferers within weeks instead of months, ... currently given under the skin (subcutaneously), new methods of ... week,s annual scientific meeting of the American College of ...
... N.C. -- For the first time, researchers have ... successfully reverse the severe, crippling bleeding disorder hemophilia ... the development of new therapies for human patients. ... Institute for Regenerative Medicine, collaborating with other institutions, ...
... Reporter , WEDNESDAY, Nov. 2 (HealthDay News) -- A compound ... hard-to-treat hemophilia patients also seems to be effective in preventing ... published in the Nov. 3 edition of the New ... didn,t last long, the results do raise the possibility that, ...
... locally advanced or high-risk prostate cancer who receive combined ... likely to die from their disease, shows clinical research ... (PMH) Cancer Program, University Health Network. The ... (doi: 10.1016/S0140-6736(11)61095-7). Principal investigator Padraig Warde, deputy head, ...
Cached Medicine News:Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 2Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 3Health News:Congress must 'go big' on physician payment reform 2Health News:Congress must 'go big' on physician payment reform 3Health News:Improved Allergy Shots Might Be on Horizon 2Health News:Gene therapy shows promise as hemophilia treatment in animal studies 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 3Health News:Radiation plus hormone therapy greatly improves survival 2
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ... angle required for large and small joint ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
Medicine Products: